Nasus Pharma
- Country
- Ownership
- -
- Employees
- -
- Market Cap
- -
- Introduction
Nasus Pharma Ltd. engages in the development of intranasal drugs for emergency medical conditions. It offers Powder-Based Intranasal (PBI) specialized product portfolio, to address acute medical conditions and public health threats. The company was founded by Udi Gilboa and Dalia Megiddo in May 2019 and is headquartered in Tel Aviv, Israel.
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
FMXIN002 in Patients at Risk of Anaphylaxis
- Conditions
- Anaphylaxis Food
- First Posted Date
- 2025-07-01
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Nasus Pharma
- Target Recruit Count
- 30
- Registration Number
- NCT07045701
- Locations
- 🇮🇱
Shamir Medical Center, Be'er Ya'aqov, Israel
Comparative Bioavailability of Intranasal Epinephrine
- Conditions
- Anaphylactic ReactionAnaphylaxis
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Nasus Pharma
- Target Recruit Count
- 12
- Registration Number
- NCT06205134
- Locations
- 🇮🇱
Clinical Pharmacology Unit, Hadassah Medical Center, Ein Karem, Jerusalem, Israel
COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19).
- Conditions
- Upper Respiratory Tract InfectionsCOVID-19
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Nasus Pharma
- Target Recruit Count
- 693
- Registration Number
- NCT05252468
- Locations
- 🇧🇬
Diagnostics and Consultation Center Convex Ltd, Sofia, Bulgaria
A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder
- Conditions
- Opioid Overdose
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Nasus Pharma
- Target Recruit Count
- 46
- Registration Number
- NCT04713709
- Locations
- 🇨🇦
Pharma Medica Research Inc, Mississauga, Ontario, Canada
Bioavailability of Nasal Epinephrine
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Nasus Pharma
- Target Recruit Count
- 12
- Registration Number
- NCT04696822
- Locations
- 🇮🇱
Hadassah Medical Center, Ein Kerem, Jerusalem, Israel